HC
ADMS

Henshaw Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Henshaw Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,272
Closed -$32.6K – 322
2020
Q1 		$32.6K Buy
+11,272
New +$50.5K ﹤0.01% 279
2019
Q4 		– Sell
-10,443
Closed -$53.4K – 313
2019
Q3 		$53.4K Hold
10,443
– – ﹤0.01% 284
2019
Q2 		$64.7K Hold
10,443
– – 0.01% 292
2019
Q1 		$74.3K Hold
10,443
– – 0.01% 282
2018
Q4 		$89.2K Buy
+10,443
New +$136K 0.01% 268

Other funds holding ADMS

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Henshaw Capital's ADMS Position: Q2 2020 in Review

Henshaw Capital sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 11,272 shares — an estimated $32.6K sold.

Henshaw Capital first reported a position in ADMS in Q4 2018 and held it in 5 quarters. The position peaked at $89.2K in Q4 2018. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • Henshaw Capital reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Henshaw Capital sold 11,272 Adamas Pharmaceuticals shares in Q2 2020, an estimated $32.6K.
  • Henshaw Capital first reported a position in Adamas Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Henshaw Capital's Adamas Pharmaceuticals position peaked at $89.2K in Q4 2018.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on Henshaw Capital's 13F filing for Q2 2020, filed 28 May 2026.